Drug intelligence / Profile preview

Embella (Espad Pharmed)

Development stage: Unknown
Lead developer: Espad Pharmed
Administration: Intradermal, Subcutaneous

Overview

Embella is a hyaluronic acid-based dermal filler developed and manufactured by Espad Pharmed for aesthetic and cosmetic procedures. It is indicated for soft-tissue augmentation, wrinkle correction, and facial volumization. Administered via dermal, subcutaneous, or intracutaneous injection, the product utilizes the physical and hygroscopic properties of cross-linked hyaluronic acid to provide immediate volume and hydration to the treated area. This mechanical filling effect smooths skin depressions and restores lost facial contours, offering a non-surgical solution for facial rejuvenation.

Brand names: Embella

Beyond the preview

Go deeper on Embella (Espad Pharmed).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Embella (Espad Pharmed).

Explore the full profile